Vivos Therapeutics

Rising Sleep Apnea Prevalence Will Accelerate Noninvasive Treatment Expansion

AnalystHighTarget

Not Invested

Consensus Narrative from 2 Analysts

Published

17 Aug 25

Updated

21 Aug 25

AnalystHighTarget's Fair Value

US$6.20

25.8% undervalued

21 Aug

US$4.60

70.4%

-0.2%

Author's Valuation

US$6.2

25.8% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$6.2

25.8% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

36.04%

Healthcare Services revenue growth rate

0.26%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$3.07m

Earnings '28

40.54x

PE Ratio '28

US$124.44m

Market Cap '28

US$124.44m

Market Cap '28

16.49m

No. shares '28

US$7.55

Share Price '28

US$7.55 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$6.20

Fair Value '25